About the Study

High Risk Medulloblastoma: A clinical study of elfornithine/DFMO as maintenance therapy after standard treatment

The purpose of this research study is to see how well the investigational drug, eflornithine HCl (DFMO) works for Medulloblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to either keep the tumors in remission or, if for active tumors, for the tumors to respond to the treatment. It will also look at the safety and tolerability of DFMO.

Interested in learning more?

Full Study Name: BCC016 Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma